233 results about "Myricetin" patented technology

The invention discloses an extractive of Taxus chinensis var.mairei leaves and a preparation method. The extractive is a straw yellow powder. The powder contains sciadopitysin the weight content of which is 65-70 percent; the sciadopitysin contains the following five components: 3-O-rutin-quercetol, 3-O-rutin-campherol, 3-O-rutin-myricetin, 7-O-glucose-campherol and 7-O-glucose-quercetol, and the total weight content of the five components in the sciadopitysin is 40-60 percent. The extractive is prepared by the preparation method comprising the steps of baking, crushing and screening, immersing into an alcohol dissolvant, ultrasonically extracting while stirring, decompressing and concentrating an extracting solution to remove alcohol, extracting with chloroform and degreasing, water phase concentrating and drying by taking fresh Taxus chinensis var.mairei leaves as raw materials. The extractive of Taxus chinensis var.mairei leaves has the functions of improving heat microcirculation, resisting arrhythmia, lowering myocardial oxygen consumption and the like and having the therapeutic and health-care function on diseases of cardiovascular system; and the preparation method has low energy consumption, short extracting time, few impurities and higher extraction efficiency.

The invention discloses a method for preparing total flavonoids of hovenia acerba. The method adopts one optional method of the solvent extraction method, the solvent extraction method, the macro-porous resin adsorption method, the liquid-liquid countercurrent distribution chromatography, the supercritical fluid extraction method or the column chromatography, or the free combination of the methods. The total flavonoids of hovenia acerba is prepared from any one part of hovenia acerba, such as fruit stems, fruits, seeds, seed-cases, roots, stems, leaves, flowers, branches, skins, skin and fruit residues, etc., and the combination thereof. The prepared total flavonoids is a combination of various flavonoid active components, wherein the total flavonoids comprises the main active components as follows: quercetin, kaempferol, (+)-dihydromyricetin, myricetin, north hovenia acerba alcohol, (+)-pyrocatechin, hovenia acerba I, hovenia acerba II, hovenia acerba III and the derivates thereof; the total percentage composition of various flavonoid components by the weight is 5% to 100%; and the preparation method is applicable to pharmaceutical industry, food industry, cosmetic industry and health-care product industry.

The invention discloses a method for extracting total flavonoids of hovenia dulcis. The method adopts the solvent extraction method and one optional method of the solvent extraction method, the macro-porous resin adsorption method, the supercritical fluid extraction method, the column chromatography or liquid-liquid countercurrent distribution chromatography, or the free combination of the methods. The total flavonoids of hovenia dulcis is extracted from any one part of hovenia acerba, such as fruit stems, fruits, seeds, seed-cases, leaves, flowers, roots, stems, branches, skins and fruit residues, etc., or the combination thereof and is further separated and purified. The prepared total flavonoids is a combination containing two or more flavonoid active components, wherein the total flavonoids comprises the main active components as follows: quercetin, kaempferol, myricetin, (+)-dihydromyricetin derivates, etc.; the total percentage composition of various flavonoid components by weight is 12% to 100%; and the preparation method is applicable to pharmaceutical industry, food industry, cosmetic industry and health-care product industry.

The invention discloses a myricetin derivative containing amide thioether thiadiazole, of which a general formula is represented as follows, wherein R is hydrocarbyl groups, phenyl groups, substituted phenyl groups, heteroaromatic ring groups or substituted heteroaromatic ring groups. The compound has high treatment and prevention effect against tobacco mosaic virus (TMV), has high anti-plant virus activity and can be used for preparing anti-plant virus pesticides. The compound has high inhibition activity on Xanthomonas axonopodis and Xanthomonas oryzae and can be used for preparing agricultural bactericides.

This invention discloses a method for extracting myricetin from Mirica rubra bark or Ampelopsis grossedentata. The method comprises: (1) extracting Mirica rubra bark or Ampelopsis grossedentata with ethanol; (2) extracting with a medium polarity organic solvent; (3) adsorbing crude myricetin by polyamide or polar macroporous resin, eluting and separating to obtain the final product. The method has such advantages as high yield, simple separation and high product purity (greater than or equal to 80%), and is suitable for mass product.

The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-β-xylopyranoside, quercetin-3-β-glucoside, quercetin-3-α-arabinopyranoside, 3′-methoxyquercetin-3-α-xylopyranoside, quercetin-3-O-(6″-p-coumaroyl)-β-galactoside, and quercetin-3-O-(6″-benzoyl)-β-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-α-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.

The invention discloses a method used for separating and identifying flavonoid matters in tobacco by adopting liquid chromatography-mass spectrography. The method comprises the following steps: a sample is ground and dried, an extractant is added according to the standard that 0.1 ml of the extractant is added into 1 mg of the sample for extraction and centrifugation, a supernatant liquor is collected, water and chloroform are added according to the standard that 0.5 ml of the water and 1 ml of the chloroform are added into 1 ml of the supernatant liquor for centrifugation, and the supernatant liquor is collected for analysis; 153+ and 151- are adopted as characteristic ions for scanning, parent ions are extracted for second level mass spectrum scanning, and an obtained spectrogram is compared with a spectral library to determine a chemical structure and verified through a reference substance; the molecules and ions of the identified matters and myricetin, dihydromyricetin, catechinic acid / epicatechin, daidzein, glycitein and glycyrrhizin / isoliquiritigenin are adopted as characteristic ions for scanning, the molecules and ions of the searched glycosylation flavonoid matters are used as the parent ions for the second level mass spectrum scanning, an obtained spectrogram is compared with the spectral library to determine a chemical structure and verified through the reference substance. According to the invention, the method is suitable for the analyzing and detecting micro even trace flavonoid matters.

This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, 3-Phenylpropyl Acetate, Oleanolic acid, ursolic acid, β-Myrcene, cinnamic acid, Luteolin-7-Glucoside, Liquiritin, (+)Limonene, Homoorientin, Swertiamarin, Embelin, Daidzein, Poncirin, (−)-Epicatechin, ergosterol. These natural products can be used to enhance the bioavailability of therapeutic agents (drugs).

The invention provides an authenticity evaluating method for a populus-type propolis based on multi-index quality control, and caffeic acid, p-coumaric acid, ferulic acid, rutin, myricetin, cinnamic acid, galangin, chrysin, pinocembrin and CAPE in the propolis are detected by high performance liquid chromatography. A mixing standard sample of caffeic acid, p-coumaric acid, ferulic acid, rutin, myricetin, cinnamic acid, galangin, chrysin, pinocembrin and CAPE is taken as a reference index in the method; wherein whether the propolis is from a populus-type material is defined by the existence or inexistence of cinnamic acid, galangin, chrysin, pinocembrin and CAPE, a poplar tree's gum and the propolis are distinguished by the existence or inexistence of caffeic acid, p-coumaric acid and ferulic acid, adulteration or no adulteration of rutin or myricetin is determined by taking rutin or myricetin as a reference; and thus a detection method for distinguishing between the poplar tree's gum and the populus-type propolis, and adulteration or no adulteration of rutin or myricetin, is constructed, and the method helps to evaluate whether a sample is from populus plants, and helps to achieve discarding of the false and retaining of the true about the populous-type propolis.

This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

The invention discloses a method for simultaneously measuring 11 flavonoid constituents in vine tea through HPLC and belongs to the technical field of medicinal plant constituent analysis.The method includes the steps that firstly, a mixed standard substance solution and a vine tea test sample solution are prepared respectively, then the mixed standard substance solution and the vine tea test sample solution are detected respectively through high performance liquid chromatography, and the contents of dihydromyricetin, dihydroquercetin, aromadendrin, naringenin, hesperetin, myricetin, myricetrin, kaempferol, quercetin, rutin and apigenin in a test sample are obtained through calculation.The measuring method is good in stability and reproducibility, easy to operate, accurate and reliable in result and capable of being applied to simultaneous measurement of multiple flavonoid constituents in the vine tea.

The invention belongs to the technical field of medicines and relates to a myricetin nanosuspension and a preparation method thereof. The myricetin nanosuspension is prepared by adopting a settling method and a high-pressure homogenization method, and the formula comprises myricetin and a stabilizer according to the weight ratio of 1: 0.25-1: 2.5. According to the preparation method provided by the invention, the formula is optimized, Tween-80, Cremophor EL and D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) are screened as the stabilizer, the prepared myricetin nanosuspension has stable nature and simple composition of the formula, the preparation process is simple, convenient and feasible, and the particle size range is 100nm-300nm; and by reducing the particle size of a medicament, the solubility and the dissolution of the myricetin are obviously improved, and the oral bioavailability and the in-vivo tissue distribution of the myricetin are further improved. In addition, the myricetin nanosuspension can be freeze-dried, and proper excipients are added into the obtained freeze-dried powder for further preparing oral liquid, tablets, granules, capsules and other different oral preparations so as to facilitate clinical applications.

The invention provides a method for composite enzymolysis-assisted extraction of an active ingredient from propolis, and belongs to the extraction technology of propolis. The method comprises the following steps of: selecting high-quality rough propolis as a raw material; removing impurities, refrigerating, crushing and then homogenously mixing a certain amount of enzymolysis agent; filling the mixed raw material on a biological enzymolysis bed; performing biological enzymolysis by adjusting parameters such as enzymolysis temperature, humidity, pH, time and the like; extracting flavonoid from the propolis in a classified way in an extraction tank by controlling factors such as alcoholic strength, solid-to-liquid ratio, temperature, pressure, time and the like; and performing reduced pressure distillation by controlling concentration temperature and vacuum degree to remove impurities and moisture. The method has the obvious advantages that: 1, a propolis enzymolysis technology and a propolis alcohol extraction technology are integrally applied to production practice, and the method has a simple process and an accurate technological parameter range and is easy in realization of industrialization; 2, the contents of flavone aglycones such as myricetin, quercetin, apigenin, pinocembrin and the like in extracted active ingredient of the propolis are increased; and 3, the antioxidative activity of a propolis enzymolysis product can be obviously improved.

The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-β-xylopyranoside, quercetin-3-β-glucoside, quercetin-3-α-arabinopyranoside, 3′-methoxyquercetin-3-α-xylopyranoside, quercetin-3-O-(6″-p-coumaroyl)-β-galactoside, and quercetin-3-O-(6″-benzoyl)-β-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-α-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.

The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-β-xylopyranoside, quercetin-3-β-glucoside, quercetin-3-α-arabinopyranoside, 3′-methoxyquercetin-3-α-xylopyranoside, quercetin-3-O-(6″-p-coumaroyl)-β-galactoside, and quercetin-3-O-(6″-benzoyl)-β-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-α-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.

The invention provides a water mask and a making method thereof, and belongs to the field of masks. The water mask is made from a hydrogel matrix, myricetin, myricetrin and dihydromyricetin according to a molar ratio of myricetin to myricetrin to dihydromyricetin of 0.8-1.2:0.8-1.2:0.8-1.2. The making method of the mask comprises the steps of grinding, stirring mixing and coating. The water mask adopting myricetin, myricetrin and dihydromyricetin extracted from natural plants as effective components of the mask is nontoxic and has no side effects on skins.

The invention discloses a synthesis method of myricetin. The method includes the steps of: adding an alkaline solution into a dihydromyricetin aqueous solution, and then performing heating under a reflux state; adding a selenium dioxide aqueous solution, then stirring at a reflux temperature for reaction, and then performing cooling to room temperature; adding acid to adjust the pH value, conducting stirring and rotary evaporation, and then performing stirring and filtering; adding an ethanol aqueous solution into a filter cake, performing pulping and filtering, flushing the filter cake with an ethanol aqueous solution, collecting the filter cake, and performing drying to obtain red selenium; combining an organic phases, and performing spin-drying till no ethanol smell, precipitating a large amount of solid, performing filtering, and flushing the filter cake with an ethanol aqueous solution to obtain a yellow solid, i.e. myricetin. The method has the advantages that: 1, the reaction issimple and easy to operate; 2, water and a small amount of ethanol are mainly used as the solvent, and the emission of three wastes is low; 3, red selenium with economic value can be recovered; 4, the obtained myricetin is high in purity; and 5, the method can achieve multiple purposes, has very good economic benefits, and is suitable for large-scale production.

The invention discloses a novel method for industrially preparing myricetin from stems and leaves of Ampelopsis sinica (Miq.) W.T.Wang of vitaceae Ampelopsis Michx or other plants of the vitaceae Ampelopsis. The novel preparation method includes the following steps: using alkaline liquor to adjust aqueous liquor or hydrous ethanol and methanol liquor into alkalescence to extract the total flavonoids in medicinal materials, condensing extraction liquor, using diluted acid to adjust the pH between 2 and 8, devitrifying and obtaining the crude extract; the crude extract is heated and extracted by using ethanol, methanol and acetone; the extraction liquor is decolored by active carbon; the myricetin can be obtained after devitrifying. The method has the advantages of simple technique, low cost, no pollution as well as being advanced, safe and practical.

The invention discloses a use of a flavonol compound, which is the use of the flavonol compound in the preparation of antihypoxic medicines, health-care foods or foods. The flavonol compound may be dihydromyricetin, myricetin, dihydroquercetin or quercetin. In the invention, the cell activity test experiment and antihypoxic test of the dihydromyricetin, myricetin, dihydroquercetin and quercetin are performed by adopting a methyl thiazolyl tetrazolium (MTT) method and H9C2 (a rat myocardial cell line). Results show that the four flavonol compounds all have obvious antihypoxic activity and can be used for preparing antihypoxic medicines, health-care products or foods.

The invention discloses epimedium source galactosyl transferase and an application of the epimedium source galactosyl transferase to the preparation of hyperoside, and belongs to the technical field of gene engineering and biological medicines. The invention provides galactosyl transferase and an application of recombinant saccharomyces cerevisiae expressing the galactosyl transferase to the catalytic synthesis of flavonoid compounds. The constructed recombinant saccharomyces cerevisiae can be enabled to catalyze the transfer of UDP-galactose to various flavone substrates such as quercetin, kaempferol, myricetin, dihydroquercetin, dihydrokaempferol, dihydromyricetin, fisetin, morin and icaritin.

The invention discloses a triazole Schiff base Myricetin derivative containing thioether, a preparation method and application thereof. The structural general formula of the derivative is shown as [A], wherein R is phenyl, substituted phenyl or aromatic heterocyclic base; and n is the number of carbon in a carbon chain, which is 3, 4 and 5 respectively. The triazole Schiff base Myricetin derivative has preferable control effect for tobacco mosaic virus, citrus canker bacteria and rice bacterial blight bacteria.

The invention relates to a medicine composition of myricetrin or / and myricetin aglycone thereof and levodopa or of levodopa and carbidopa and an application of myricetrin or / and myricetin aglycone thereof as a synergist in preparation of a medicine used for treating Parkinson. In vitro activity determination finds that IC50 of myricetrin and myricetin inhibiting catechol-O-methyltransferase (COMT) can be a micromole-nanomole scale. Rat overall pharmacokinetic study finds that blood concentration of levodopa can be increased after myricetrin and myricetin aglycone thereof and levodopa are used jointly; and myricetrin and myricetin aglycone thereof are high in safety, no obvious toxicity is produced to main visceral organ cells of a human body, and no active intermediate is produced by virtue of metabolism activation and further no damage done to organs such as liver and kidney is initiated, so that the myricetrin and myricetin aglycone thereof have a good application prospect in adjuvant therapy of Parkinson.

A purified green tea extract is improved in bitterness and aftertaste.The purified green tea extract, which comprises satisfying the following conditions:(1) a ratio of a sum of content weights of (A) myricetin, (B) quercetin and (C) kaempferol to a sum of content weights of (D) epigallocatechin gallate and (E) gallocatechingallate, ((A)+(B)+(C)) / ((D)+(E)), is from 0.0000001 to 0.010,(2) a sum of content weights of (D) the epigallocatechin gallate and (E) the gallocatechin gallate in non-polymer catechins, ((D)+(E))), is from 0.01 to 29 wt %, and(3) a percentage of gallate body in the non-polymer catechins is from 0.01 to 49 wt %.

The invention discloses a myricetin pharmaceutical eutectic crystal and a preparation method thereof. The myricetin pharmaceutical eutectic crystal uses myricetin as the active pharmaceutical ingredients, uses theine, nicotinamide, pyrazinamide or 4-cyanopyridine as the precursors, and is a myricetin-theine eutectic crystal, a myricetin-nicotinamide eutectic crystal, a myricetin-pyrazinamide eutectic crystal or a myricetin-4-cyanopyridine eutectic crystal formed through intermolecular hydrogen bonds. The eutectic crystals are prepared by adopting the solution mediating crystal transformation method. The myricetin pharmaceutical eutectic crystal provided by the invention inherits the pharmacological activity of the myricetin; meanwhile, the solubleness, the dissolution rate and the stability of the myricetin pharmaceutical eutectic crystal are all significantly improved as compared with those of the myricetin; the myricetin pharmaceutical eutectic crystal facilitates the development of pharmaceutic preparation and the wide applications of the myricetin in the field of medicine.

The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin, (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain diseases of the CNS system and related disorders.

The invention discloses a new medical use of myricetin, belonging to the technology field of medicines. Through acetic acid writhing test, formaldehyde-induced pain test, glacial acetic acid-induced capillary permeability test, dimethybenzene-induced mouse ear swelling test, egg white and carrageenin-induced paw edema test, test of leukocytoplania of pleurisy caused by carboxymethyl cellulose, granuloma (chronic) inflammation test, and screening of adjuvant arthritis animal models with primary and secondary inflammations, the myricetin is found to have high antiphlogistic and analgesic activity and can prevent and treat adjuvant arthritis, the antiphlogistic activity of myricetin is equivalent to that of aspirin but no gastrointestinal toxicity, and the anti-rheumatoid arthritis activity of myricetin is equivalent to that of Tripterygium wilfordii, and the myricetin has liver protecting effect and is an ideal drug for preventing and treating acute and chronic inflammations and rheumatoid arthritis. The myricetin can be prepared into various preparations with pharmaceutically-acceptable carrier for relieving inflammations, reliving pain and treating rheumatoid arthritis.

The invention relates to a method extracting myricetin by hovenia dulcis thumb, which comprises the steps of hovenia dulcis thunb extraction, extract concentration, resin adsorption and separation, silica gel column purification and recrystallization. Compared with prior art, the extraction method is carried out by medicinal material pretreatment, microwave extraction, the extraction rate by the microwave extraction is obvious higher than that of other extraction methods, and the myricetin with high purity (purity is greater than or equal to 99.8%) can be finally obtained through resin separation and the silica gel column purification, and the extraction rate can reach 95%. The invention provides the effective method for extracting a lot of myricetin by hovenia dulcis thumb.

The invention provides a preparation method of myricetin. The preparation method comprises the following steps: mixing dihydromyricetin with alcohols, then adding a sodium hypochlorite solution and a catalyst to carry out reactions, and after the reactions, keeping on adding a sodium hypochlorite solution to obtain myricetin; wherein the alcohol is methanol or ethanol, and the catalyst is anhydrous aluminum trichloride or anhydrous iron trichloride. According to the preparation method, dihydromyricetin is taken as the primary raw material, myricetin is prepared from dihydromyricetin through semi-synthesis, dihydromyricetin is extracted from vine tea, the content is 98% or more, the cost is low, the operation is simple, the product yield is high, the product does not need refinement, the content is 98% or more, and the preparation method is suitable for industrial production.

The present invention relates to a preparation method of tengchasu dispersion tablet and its application. Said tengchasu dispersion tablet can be used for making health-care food and medicine for preventing and curing the diseases of hyperglycemia, hyperlipemia, angiocardiopathy and cerebrovascular diseases. Its main effective component includes dihydromyricetin 5-95% and myricetin 95-5%. Besides, said invention also provides the concrete steps of its preparation method.

The invention relates to a myricetin extraction process, which belongs to the technical field of natural pharmaceutical chemistry extraction. The myricetin extraction process comprises the following steps: (1) crushing raw material containing myricetin, adding acid the PH value of which is 4-5, and controlling the temperature to be 70-80 DEG C for 1-3 hours; (2) centrifuging the raw material treated by the step (1) to remove solid-contained matter, and keeping supernate; (3) adding 80-90 percent of ethanol in the supernate prepared by the step (2) in a proportion of 1:5-10 so as to extract the myricetin to prepare extracting solution, wherein the extracting time is controlled to be 2-4 hours; (4) concentrating the extracting solution at the temperature of 60-70 DEG C to prepare concentrated extracting solution, wherein the concentrated extracting solution is 1 / 5-1 / 3 of the extracting solution; and (5) enabling the concentrated extracting solution to stand for 5 hours or more, and thenfiltering out mother liquor to prepare the myricetin. The purity of the myricetin prepared by the extraction process can reach 80 percent, and the yield thereof is about 15 percent.